LAGUNA HILLS, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Sonendo®, Inc., — The developer of a breakthrough technology that offers an alternative to standard root canal therapy, today announced the appointment of John (Jack) Glenn as Chief Financial Officer. Mr. Glenn brings 25 years of financial leadership experience within public and private companies in the life science industry.
“I am thrilled to welcome Jack to the Sonendo team,” said Bjarne Bergheim, President and CEO of Sonendo. “Jack’s leadership and public company experience will position Sonendo for exciting opportunities in the years ahead as we continue to pursue transformative technologies within the dental space.”
Before joining Sonendo, Glenn most recently served as Chief Financial Officer of Armetheon Corporation, a privately held San Francisco Bay Area based specialty biopharmaceutical company. Prior to this, Glenn served as Chief Financial Officer of publicly traded Solta Medical, where he played a key role in the identification, negotiation and structuring of several acquisitions, public equity offerings and debt financings and assisted in the company’s strategic acquisition by Valeant Pharmaceutical. Previously Glenn served as Chief Financial Officer at publicly traded Cholestech, which was acquired by Alere Medical and also served as Chief Financial Officer at Invivo Corporation, a publicly traded company, which was sold to Intermagnetics General Corporation. Mr. Glenn earned his MBA in Finance from Santa Clara University and his B.S. in Business Administration from the University of Nevada.
“Sonendo is at an exciting stage in the Company’s pursuit of changing the standard of care for root canal therapy. I’m excited to join the Sonendo organization and help realize the value of this innovative technology,” Glenn said.
Sonendo, Inc. is a privately held, venture-backed company developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The first commercially available product from Sonendo, the GentleWave® System, available in the US, shows significant improvements in clinical efficacy, and treatment efficiency when compared to standard root canal techniques1-2. For more information, please visit: www.sonendo.com
1Molina B et al. (2015) J Endod. 41:1701-05. 2Haapasalo M et al. (2014) J Endod. 40:1178-81.
This announcement contains forward-looking statements based on management's beliefs, assumptions and expectations on information currently available to management. All statements that address events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations on the timing and progress of research and development activities. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sonendo does not assume any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.
Media Contact: Bob Guyatt Vice President of Marketing 949.766.3636